A gene therapy startup backed by two key biopharmas and two premier biotech VC firms has ceased operations.

California biotech Coda Biotherapeutics shut down recently, investors Versant Ventures and MPM Capital confirmed to Endpoints News Tuesday night, declining to provide further details. The upstart had presented preclinical data on its program for focal epilepsy last summer but had not provided an update since then. MPM removed Coda from its portfolio page in recent weeks, per internet archives, and the biotech’s LinkedIn page has been wiped.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

A Sofinnova-backed CAR-T maker has shut down its New York and Princeton, NJ sites and will continue operating out of its Paris hub.

Mnemo Therapeutics turned the lights off at its US operations effective immediately on Feb. 23, according to employees’ posts on LinkedIn and confirmation from co-founder and operating chief Alain Maiore.

“When Sebastian [Amigorena] and I started Mnemo Tx, we were looking to build a company where the human value of ‘standing shoulder to shoulder’ in difficult time would typify the DNA of our teams across the ocean,” Maiore wrote on LinkedIn in recent days. “The decision we had to make about shutting down our US operations, to move back our CT effort to Europe, next to our target discovery platform was a very difficult one.”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. As chief business officer and strategy chief for the Broad over a decade-long stretch, he’d worked with all the big names in a scientific discipline that promises to upend the therapeutics field — eventually. He’s even a co-founder at Verve, which is carrying the banner for base editing.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN